Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Up 136.0% in January

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 31st total of 232,000 shares. Based on an average daily volume of 322,600 shares, the days-to-cover ratio is currently 1.7 days. Currently, 2.7% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in Aadi Bioscience during the third quarter worth approximately $32,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Aadi Bioscience during the 2nd quarter worth approximately $37,000. Peapod Lane Capital LLC acquired a new stake in Aadi Bioscience during the 4th quarter valued at $1,397,000. Finally, BML Capital Management LLC bought a new position in Aadi Bioscience during the third quarter worth $4,120,000. 52.08% of the stock is currently owned by institutional investors.

Aadi Bioscience Stock Down 0.3 %

Shares of NASDAQ AADI opened at $2.88 on Friday. Aadi Bioscience has a 12-month low of $1.21 and a 12-month high of $3.81. The firm’s 50-day simple moving average is $2.82 and its 200 day simple moving average is $2.16. The company has a market cap of $70.99 million, a price-to-earnings ratio of -1.26 and a beta of 0.65.

Aadi Bioscience (NASDAQ:AADI) last released its earnings results on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, hitting analysts’ consensus estimates of ($0.46). Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The firm had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.55 million. During the same quarter in the previous year, the business earned ($0.60) EPS. On average, equities analysts expect that Aadi Bioscience will post -2.04 earnings per share for the current year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.